Ameritas Advisory Services LLC Has $2.34 Million Position in Amgen Inc. $AMGN

Ameritas Advisory Services LLC lifted its position in Amgen Inc. (NASDAQ:AMGN) by 88.4% during the third quarter, HoldingsChannel.com reports. The fund owned 8,279 shares of the medical research company’s stock after purchasing an additional 3,884 shares during the period. Ameritas Advisory Services LLC’s holdings in Amgen were worth $2,336,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in AMGN. TAGStone Capital Inc. raised its holdings in Amgen by 0.8% during the 3rd quarter. TAGStone Capital Inc. now owns 4,101 shares of the medical research company’s stock worth $1,157,000 after buying an additional 32 shares during the period. Wealth Quarterback LLC grew its stake in Amgen by 1.6% in the third quarter. Wealth Quarterback LLC now owns 2,210 shares of the medical research company’s stock valued at $624,000 after purchasing an additional 34 shares in the last quarter. DDFG Inc increased its holdings in Amgen by 1.1% during the third quarter. DDFG Inc now owns 3,014 shares of the medical research company’s stock worth $850,000 after buying an additional 34 shares during the last quarter. Nicholson Wealth Management Group LLC raised its holdings in shares of Amgen by 0.6% in the 2nd quarter. Nicholson Wealth Management Group LLC now owns 5,918 shares of the medical research company’s stock valued at $1,652,000 after purchasing an additional 35 shares during the period. Finally, LS Investment Advisors LLC raised its stake in Amgen by 4.1% in the third quarter. LS Investment Advisors LLC now owns 885 shares of the medical research company’s stock valued at $250,000 after buying an additional 35 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Stock Up 0.8%

Shares of NASDAQ:AMGN opened at $369.19 on Friday. The company has a market capitalization of $198.80 billion, a price-to-earnings ratio of 25.94, a P/E/G ratio of 3.75 and a beta of 0.46. Amgen Inc. has a 1 year low of $261.43 and a 1 year high of $385.12. The business’s 50-day moving average is $337.47 and its 200-day moving average is $313.61. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating the consensus estimate of $4.76 by $0.53. The company had revenue of $9.87 billion during the quarter, compared to analyst estimates of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. Amgen’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities research analysts predict that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be paid a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 2.7%. This is a boost from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date of this dividend is Friday, February 13th. Amgen’s payout ratio is 66.90%.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: European Commission approval for Uplinza (amifampridine) for generalized myasthenia gravis expands Amgen’s labelled indications in Europe and supports incremental near-term revenue potential for the product. Amgen wins EC approval for Uplinza in gMG
• Positive Sentiment: Amgen announced an increase to its dividend to $2.52, which boosts yield and signals management confidence in cash flow — typically supportive for a large-cap, dividend-oriented stock. Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.52
• Positive Sentiment: Unusually large call-option activity (roughly 320,232 calls bought) points to short-term bullish positioning by some investors, which can amplify upside moves in the stock. (No source link provided in feed)
• Neutral Sentiment: Amgen will present at Citi’s 2026 Virtual Oncology Leadership Summit — a standard investor relations event that raises visibility on oncology programs but is not intrinsically catalytic. AMGEN TO PRESENT AT CITI’S 2026 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT
• Neutral Sentiment: Analyst notes are mixed: Argus reiterated a Buy with a $400 target while Guggenheim reaffirmed a Hold — this provides conflicting signals but keeps the stock in analysts’ focus. Here’s What Argus Research and Guggenheim Are Saying About Amgen Inc. (AMGN)
• Neutral Sentiment: Industry coverage (CNBC) on pharma’s resetting priorities — pricing, pipelines and patent cliffs — is a sector-level backdrop that could affect sentiment for large-cap drugmakers like Amgen but is not company-specific. Prices, pipelines and patent cliffs: Inside pharma’s big reset
• Neutral Sentiment: Recent entries on short interest in the data feed appear to be reporting zero shares / NaN changes (likely a reporting glitch) and do not signal a meaningful rise in short positioning. (No link provided)

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 3,139 shares of the company’s stock in a transaction on Thursday, November 20th. The shares were sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the transaction, the senior vice president owned 7,225 shares in the company, valued at approximately $2,436,703.50. This represents a 30.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.76% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on AMGN. Cantor Fitzgerald raised their target price on shares of Amgen from $315.00 to $350.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 4th. Mizuho upped their target price on Amgen from $280.00 to $295.00 and gave the company an “outperform” rating in a research report on Tuesday. Wells Fargo & Company increased their price target on shares of Amgen from $300.00 to $325.00 and gave the stock an “equal weight” rating in a research report on Wednesday, December 10th. Truist Financial lifted their target price on Amgen from $318.00 to $319.00 and gave the company a “hold” rating in a research report on Thursday, January 8th. Finally, Leerink Partners boosted their target price on shares of Amgen from $305.00 to $355.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 4th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $354.04.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.